Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Riel, P. L. C. M.
Right arrow Articles by van de Putte, L. B. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by van Riel, P. L. C. M.
Right arrow Articles by van de Putte, L. B. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 British Society for Rheumatology

Long-Term Usage and Side-Effect Profile of Sulphasalazine in Rheumatoid Arthritis

P. L. C. M. van Riel, A. M. van Gestel and L. B. A. van de Putte

Department of Rheumatology, University Hospital Nijmegen The Netherlands

Correspondense to: P. L. C. M. Van Riel, Department of Rheumatology, University Hospital Nijmegen, Goert Grootplein 8, 6525 GA Nijmegen, The Netherlands


  Abstract

In a cohort of patients with early rheumatoid arthritis, sulphasalazine (SASP) was mainly given as a first-choice second-line agent. SASP resulted in a significantly better survival rate compared with hydroxychloroquine, which is also given as a first-choice agent. When the survival rate of SASP was compared with that of aurothioglucose, both given as second-choice agents, again, a statistically significant better survival rate was found for SASP. In 9% of the patients, SASP could be withdrawn as a complete remission was obtained. Adverse reactions occurred mainly during the first 3 months of treatment, and in 20% of patients these were severe enough to stop treatment. Gastrointestinal adverse reactions were most frequently observed, and all adverse reactions were completely reversible after treatment withdrawal. Treatment was started with a standard dose of 2000 mg/day. However, in ~30% of the patients, this dose was increased up to 3000 mg/day and, in another 30%, the dose was decreased to 1500 or 1000 mg/day.

KEY WORDS: Rheumatoid arthritis, Sulphasalazine, Hydroxychloroquine, Aurothioglucose, Survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.